Protandric Simultaneous Hermaphroditism in Parhippolyte Misticia (Clark, 1989) (Caridea: Hippolytidae): Implications for the Evolution of Mixed Sexual Systems in Shrimp

The sexual system of the shrimp Parhippolyte misticia (Clark, 1989), inhabiting the rocky subtidal at Okinawa, Japan and Kimbe Bay, Papua New Guinea, was examined. Dissections suggested that the population consisted of male phase (MP) and functional simultaneous euhermaphrodite (EH) individuals. MPs have cincinulli and appendices masculinae on the first and second pair of pleopods, respectively, gonopores located at the coxae of the third pair of walking legs, and ovotestes with a well-developed male portion containing sperm, but an undeveloped female portion. EHs lacked appendices masculinae and cincinulli. However, they have male gonopores and ovotestes with well-developed ovaries containing mature oocytes and testes with sperm. When EHs were maintained in pairs, both shrimp molted and spawned eggs which attached below the pleon and developed as embryos, demonstrating that EHs can reproduce as males and inseminate other Elis acting as females. These results demonstrate that P misticia is a protandric simultaneous hermaphrodite, as reported before for other shrimp of the genera Lysmata and Exhippolysmata. Also, these results suggest that protandric simultaneous hermaphroditism might have evolved more than once independently in shrimp from the diverse and species-rich Infraorder Caridea. Future research aimed at disentangling the phylogenetic relationship of Parhippolyte, Lysmata, Exhippolysmata and other closely related genera (Calliasmata, Lysmatella, Barbouria) and describing the sociobiology of additional representatives from the genera above is needed to understand the evolutionary history of sexual systems in caridean shrimp. © The Crustacean Society, 2012

High PKCλ expression is required for ALDH1-positive cancer stem cell function and indicates a poor clinical outcome in late-stage breast cancer patients.

Despite development of markers for identification of cancer stem cells, the mechanism underlying the survival and division of cancer stem cells in breast cancer remains unclear. Here we report that PKCλ expression was enriched in basal-like breast cancer, among breast cancer subtypes, and was correlated with ALDH1A3 expression (p = 0.016, χ2-test). Late stage breast cancer patients expressing PKCλhigh and ALDH1A3high had poorer disease-specific survival than those expressing PKCλlow and ALDH1A3low (p = 0.018, log rank test for Kaplan-Meier survival curves: hazard ratio 2.58, 95% CI 1.24-5.37, p = 0.011, multivariate Cox regression analysis). Functional inhibition of PKCλ through siRNA-mediated knockdown or CRISPR-Cas9-mediated knockout in ALDH1high MDA-MB 157 and MDA-MB 468 basal-like breast cancer cells led to increases in the numbers of trypan blue-positive and active-caspase 3-positive cells, as well as suppression of tumor-sphere formation and cell migration. Furthermore, the amount of CASP3 and PARP mRNA and the level of cleaved caspase-3 protein were enhanced in PKCλ-deficient ALDH1high cells. An Apoptosis inhibitor (z-VAD-FMK) suppressed the enhancement of cell death as well as the levels of cleaved caspase-3 protein in PKCλ deficient ALDH1high cells. It also altered the asymmetric/symmetric distribution ratio of ALDH1A3 protein. In addition, PKCλ knockdown led to increases in cellular ROS levels in ALDH1high cells. These results suggest that PKCλ is essential for cancer cell survival and migration, tumorigenesis, the asymmetric distribution of ALDH1A3 protein among cancer cells, and the maintenance of low ROS levels in ALDH1-positive breast cancer stem cells. This makes it a key contributor to the poorer prognosis seen in late-stage breast cancer patients

Comparison of two screening tests for HIV-Associated Neurocognitive Disorder suspected Japanese patients with respect to cART usage

<div><p>In this study, we demonstrated the pervasiveness of HIV-associated neurocognitive disorders (HAND) among a selection of Japanese patients as well as evaluated and compared the Mini Mental State Examination (MMSE) and the International HIV Dementia Scale (IHDS) for use as a screening tool among combination anti-retroviral therapy (cART)-naïve and cART experienced patients. The MMSE and the IHDS have both been used as HAND screening tests around the world with variable success. It has been reported the increased usage of cART the utility of these screening tests may have been diminished due to the decreased severity of impairment and the altered pattern of neurocognitive impairments in cART era HAND patients. It is therefore possible the MMSE and the IHDS may still be useful among cART-naïve patients even in the cART era. However, only one study has investigated and compared the screening results of the IHDS among cART-naïve and cART experienced patients. All HIV positive patients who visited, or were admitted, to the Ryukyu University Hospital between January 2009 and March 2014 were evaluated for inclusion. Selected patients (n = 49) had data without omission for all tests. The overall prevalence of HAND in our cohort was 44%. The area under the curve (AUC), for all subjects using the MMSE and the IHDS, were 0.60 and 0.69, respectively. However, the AUC among cART-naïve patients were 0.58 and 0.76 for the MMSE and the IHDS, respectively. Whereas, cART experienced patients had an AUC of 0.60 and 0.61, respectively. Overall, the MMSE demonstrated a poor screening ability for HAND, regardless of cART usage (the cut-off value of 27 had a Youden's J-Index of 0.1, in all groups). Alternatively, the IHDS was moderately useful for HAND screening among cART-naïve patients (the cut-off value of 11 had a Youden's J-Index of 0.4), but performed poorly as a screening test among cART experienced patients (the cut-off value of 11 had a Youden's J-Index of 0.1).</p></div

Patient score distribution for MMSE and IHDS (n = 49).

<p>Black and white bar indicate cART-naive and cART experienced patients, respectively.</p

Patient scores for each neurophychological test for HAND diagnosis (n = 49).

<p>Impairment (Imp) was considered as mental deterioration of at least 1 standard deviation. Non-impairment (non-Imp) patients were considered as having minimal mental deterioration ranging from less than 1 standard deviation to normal cognitive abilities. Abbreviations: DST: Digit Symbol Test, TMT-A; Trail Making Test Part A, TMT-B; Trail Making Test Part B, ST; Stroop Test, DS; Digit Span.</p

ROC curve of MMSE and IHDS among cART-naïve (n = 27) and cART experienced patients (n = 22).

<p>Receiver Operator Characteristic (ROC) curve for cART-naïve and cART experienced patients generated by using the results from the neuropsychological test battery as a gold standard for HAND diagnosis.</p

ROC curve of MMSE and IHDS among all subjects (n = 49).

<p>Receiver Operator Characteristic (ROC) curve generated by using the results from the neuropsychological test battery as a gold standard for HAND diagnosis.</p

Patient background and laboratory findings.

<p>Patient background and laboratory findings.</p